JH_0920



NAME OF DRUG : JH_0920

ALSO KNOWN AS : JH_0920

LABORATORY : JOYCEBiotech

STATUS AND ADVANCEMENT

Type of drug : inhibit anaerobic metabolism in eukaryotic

Clinical trials advancement : Preclinic

Estimated time to market : 136 months.

LABORATORY ABSTRACT ON THE DRUG

JOYCE Biotech's lead candidate for development, JH-0920, has been engineered to inhibit anaerobic metabolism in eukaryotic cells possessing mitochondria & thus inhibit the occurrence of the Bioenergetic Reprogramming fundamental to NASH pathogenesis and ongoing NASH pathophysiology.

JH-0920 has demonstrated the following characteristics in-vivo:

  1. Improved insulin sensitivity

  2. Significant anti-inflammatory effects

  3. Reduced levels of oxidative injury

  4. Significantly reduced activity of bioenergetic pathways associated with anaerobic metabolism and/or "aerobic glycolysis"

RECENT NEWS ON JH_0920

SOME PUBLICATIONS RELATED WITH JH_0920

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH JH_0920


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE